CGH
NKTR icon

Crossmark Global Holdings’s Nektar Therapeutics NKTR Stock Holding History

Crossmark Global Holdings’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,108
Closed -$12K – 1326
2023
Q1 		$12K Hold
1,108
– – ﹤0.01% 1294
2022
Q4 		$38K Hold
1,108
– – ﹤0.01% 1250
2022
Q3 		$53K Sell
1,108
-12
-1% -$714 ﹤0.01% 1236
2022
Q2 		$63K Sell
1,120
-176
-14% -$11.1K ﹤0.01% 1267
2022
Q1 		$104K Buy
1,296
+25
+2% +$3.7K ﹤0.01% 1331
2021
Q4 		$258K Buy
1,271
+156
+14% +$33.8K 0.01% 1221
2021
Q3 		$300K Buy
1,115
+7
+0.6% +$1.68K 0.01% 1168
2021
Q2 		$285K Buy
1,108
+86
+8% +$23.8K 0.01% 1206
2021
Q1 		$307K Buy
1,022
+6
+0.6% +$1.87K 0.01% 1160
2020
Q4 		$259K Buy
1,016
+10
+1% +$2.58K 0.01% 1172
2020
Q3 		$250K Buy
1,006
+7
+0.7% +$2.2K 0.01% 1111
2020
Q2 		$347K Buy
999
+67
+7% +$20.9K 0.01% 935
2020
Q1 		$250K Sell
932
-41
-4% -$12.7K 0.01% 945
2019
Q4 		$315K Buy
973
+81
+9% +$23.5K 0.01% 1092
2019
Q3 		$244K Sell
892
-58
-6% -$21.3K 0.01% 1165
2019
Q2 		$507K Buy
950
+20
+2% +$10K 0.01% 804
2019
Q1 		$468K Buy
930
+20
+2% +$11.9K 0.01% 848
2018
Q4 		$448K Sell
910
-270
-23% -$163K 0.01% 812
2018
Q3 		$1.08M Sell
1,180
-1
-0.1% -$854 0.03% 578
2018
Q2 		$865K Buy
1,181
+251
+27% +$289K 0.02% 661
2018
Q1 		$1.48M Sell
930
-1,081
-54% -$1.39M 0.04% 497
2017
Q4 		$1.8M Buy
2,011
+55
+3% +$32.5K 0.04% 458
2017
Q3 		$704K Buy
+1,956
New +$612K 0.02% 766
2016
Q3 		$704K Buy
+1,956
New +$504K 0.02% 766

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Crossmark Global Holdings's NKTR Position: Q2 2023 in Review

Crossmark Global Holdings sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 1,108 shares — an estimated $12K sold.

Crossmark Global Holdings first reported a position in NKTR in Q3 2016 and held it in 24 quarters. The position peaked at $1.8M in Q4 2017. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Crossmark Global Holdings reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Crossmark Global Holdings sold 1,108 Nektar Therapeutics shares in Q2 2023, an estimated $12K.
  • Crossmark Global Holdings first reported a position in Nektar Therapeutics in Q3 2016 and held it in 24 quarters.
  • Crossmark Global Holdings's Nektar Therapeutics position peaked at $1.8M in Q4 2017.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Crossmark Global Holdings's 13F filing for Q2 2023, filed 31 Jul 2023.